Colon cancer is one of the most common internal malignancies. Colorectal cancer is second leading cause of deaths in the United States. Various approaches available for The poor site specificity of pH dependent systems, because of large variation in the pH of gastrointestinal tract, was well established. The timed-release systems release their load after a predetermined period of administration. These are designed to resist the release of the drug in stomach and small intestine and release of the drug takes place in colon. Methotrexate (MTX) is a drug of choice in the treatment of colon cancer and now a days rheumatic disease. MTX is a folate antimetabolite. It is an analog of aminopterin, which is also derived from folic acid. MTX has since been used in the treatment of various malignancies including osteosarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cutaneous T cell lymphoma (mycosis fungoides), head and neck cancer, lung cancer, colon cancer and breast cancer. The conventional dosage forms which are used for colorectal cancer normally dissolve and absorbs in the stomach and small intestine; thus a very less quantity of dose of drug reaches to colonic region. Aim of present work is to develop and characterize colon targeted tablet of MTX for treatment of colorectal cancer using different polymer and excipient by compression coating technology.
